Prescriber's Corner

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease

Avani Yenamandra,(1) PharmD, and Dennis Marjoncu,(2) PharmD, BCOP

From (1) Yale New Haven Hospital, New Haven, Connecticut; (2) Methodist University Hospital, Memphis, Tennessee

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Avani Yenamandra, PharmD, 20 York Street, New Haven, CT 06501. E-mail: avani.yenamandra@ynhh.org


J Adv Pract Oncol 2020;11(8):873–877 | https://doi.org/10.6004/jadpro.2020.11.8.7 | © 2020 Harborside™


  

ABSTRACT

Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology, which leads to hemolysis, increased viscosity, and acute vaso-occlusive episodes. Novel agents have been developed to target the pathophysiology of SCD and decrease the frequency of SCD complications. Voxelotor (Oxbryta) is an HbS polymerization inhibitor that is approved by the U.S. Food & Drug Administration for the treatment of SCD in adults and pediatric patients 12 years and older. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.